Using Data-Driven Algorithms with Large-Scale Plasma Proteomic Data to Discover Novel Biomarkers for Diagnosing Depression.

Journal: Journal of proteome research
Published Date:

Abstract

Given recent technological advances in proteomics, it is now possible to quantify plasma proteomes in large cohorts of patients to screen for biomarkers and to guide the early diagnosis and treatment of depression. Here we used CatBoost machine learning to model and discover biomarkers of depression in UK Biobank data sets (depression = 4,479, healthy control = 19,821). CatBoost was employed for model construction, with Shapley Additive Explanations (SHAP) being utilized to interpret the resulting model. Model performance was corroborated through 5-fold cross-validation, and its diagnostic efficacy was evaluated based on the area under the receiver operating characteristic (AUC) curve. A total of 45 depression-related proteins were screened based on the top 20 important features output by the CatBoost model in six data sets. Of the nine diagnostic models for depression, the performance of the traditional risk factor model was improved after the addition of proteomic data, with the best model having an average AUC of 0.764 in the test sets. KEGG pathway analysis of 45 screened proteins showed that the most significant pathway involved was the cytokine-cytokine receptor interaction. It is feasible to explore diagnostic biomarkers of depression using data-driven machine learning methods and large-scale data sets, although the results require validation.

Authors

  • Simeng Ma
    Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan 430060, China.
  • Ruiling Li
    Nursing College of Shanxi Medical University, Taiyuan, 030001, China.
  • Qian Gong
    Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan 430060, China.
  • Honggang Lv
    Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan 430060, China.
  • Zipeng Deng
    Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan, China.
  • Beibei Wang
    School of Control and Mechanical Engineering, Tianjin Chengjian University, Tianjin 300384, China.
  • Lihua Yao
    Jiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
  • Lijun Kang
    Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan, China.
  • Dan Xiang
    Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan, China.
  • Jun Yang
    Cardiovascular Endocrinology Laboratory, Hudson Institute of Medical Research, Clayton, Victoria, Australia; Department of Medicine, Monash University, Clayton, Victoria, Australia.
  • Zhongchun Liu
    Department of PsychiatryRenmin Hospital of Wuhan University Wuhan 430074 China.